Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

<b>Background/Objectives</b>: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify fa...

Full description

Saved in:
Bibliographic Details
Main Authors: Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki, Toshihiko Wakabayashi, Ryuta Saito
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Neurology International
Subjects:
lasmiditan
migraine
50 mg
Online Access:https://www.mdpi.com/2035-8377/17/5/62
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items